A naukri.com initiative
Bioengineer
7d
20
Image Credit: Bioengineer
Nanotech Targets Glioblastoma Resection Margins Locoregionally
- Glioblastoma multiforme (GBM) poses a significant challenge due to its aggressive nature, infiltrative cells, and poor prognosis, despite current treatment strategies.
- The interval between tumor resection and adjuvant therapies allows residual glioma cells to proliferate, limiting the effectiveness of treatments.
- Locoregional therapeutic strategies are being explored to target residual tumor cells in the resection margin more effectively and promptly.
- Nanotechnology plays a crucial role in delivering targeted therapies to glioblastoma resection margins, offering precise drug delivery and minimizing systemic toxicity.
- Innovations focus on nanoparticle drug delivery systems that can penetrate the brain matrix, target tumor cells, and release drugs effectively.
- Challenges remain in the heterogeneity of glioblastoma tumors, safety of nanoparticles, and regulatory standards for clinical translation.
- Combining nanotherapeutic regimens with immunomodulatory strategies shows promise in enhancing anti-tumoral activity and surveillance within resection margins.
- The potential of locoregional nanotechnologies extends beyond glioblastoma to other brain malignancies, offering personalized treatment options.
- Future advancements may involve real-time intraoperative imaging and novel targeting ligands to enhance nanoparticle localization and treatment precision.
- Locoregional nanotechnologies present a promising frontier in glioblastoma treatment, aiming for durable disease control and improved patient outcomes.
Read Full Article
1 Like
For uninterrupted reading, download the app